22nd Annual Cancer Immunotherapy Symposium of the Cancer Research Institute

New York, New York
Monday, October 06, 2014

  CIC Satellite Meeting: Development of Surrogate Endpoints for Cancer Immunotherapy
  Sunday, October 5, 2014
  Session 1: Now What Do We Do: De-Risking Immunotherapy 
Chaired by Patrick Hwu
   Registration and Continental Breakfast, 8:00 am
  Introduction, 9:00 am
   Patrick Hwu, The University of Texas MD Anderson Cancer Center
  Role of Preclinical Models, 9:15-10:30 am
    Ira Mellman, Genentech
    Doug Fearon, Cold Spring Harbor Laboratory; Weill Cornell Medical College
    John Wherry, University of Pennsylvania        
  Panel Discussion, Ira Mellman, Moderator
   10:30 am Refreshment Break
  Getting the Most Out of Phase 1 Studies, 11:00 am-12:30 pm
   Daniel Chen, Genentech
   Michael Kalos, Eli Lilly
   Robert Vonderheide, University of Pennsylvania
  Panel Discussion, Robert Vonderheide, Moderator
  Session 2: Surrogate Endpoints in Late-Stage Trial Development 
Chaired by Axel Hoos
  Introduction, 1:30 pm
   Axel Hoos, GlaxoSmithKline
  Milestone Survival, 1:45 pm
   Tai Chen, Bristol-Myers Squibb
   Jedd Wolchok, Memorial Sloan Kettering Cancer Center, Commentary
  Disease Control Rate (Stable Disease by RECIST and irRC), 2:15 pm
   Ramy Ibrahim, AstraZeneca
   Keith Flaherty, Massachusetts General Hospital, Commentary 
   2:45 pm Refreshment Break
  PFS (RECIST and irRC), 3:00 pm
   Eric Rubin, Merck
   Keith Flaherty, Massachusetts General Hospital, Commentary
  Immunotherapy Patterns of Response, ORR (RECIST, irRC, other patterns), 3:30 pm
   Dan Chen, Genentech
   Jedd Wolchok, Memorial Sloan Kettering Cancer Center, Commentary
  Panel Discussion, 4:00 pm
   
  Cancer Immunotherapy: Out of the Gate
  Monday, October 6, 2014
  7:00 am  Registration and Continental Breakfast
  Welcoming Address
  8:00 am Jill O'Donnell-Tormey, Cancer Research Institute, New York, NY
  Keynote Address
  8:10 am Leiping Chen, Yale School of Medicine, New Haven, CT
2014 William B. Coley Lecture

  Session 1: Genomics and Cancer Heterogeneity 8:40 a.m. - 11:05 a.m.
Chaired by Robert Schreiber
  8:40 am Robert Schreiber, Washington University School of Medicine, St. Louis, MO
Genomics approach to cancer immunotherapy
  9:10 am Alexandra Snyder, Memorial Sloan-Kettering Cancer Center, New York, NY
Exome sequencing and the neoantigen landscape underlying clinical benefit from ipilimumab in metastatic melanoma
  9:40 am


           
10:10 am
Ton Schumacher, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Neo-antigens in human cancer

Refreshment Break
  10:35 am Catherine Wu, Dana-Farber Cancer Institute and the Broad Institute, Cambridge, MA
The evolutionary landscape of CLL: Therapeutic implications
 
  Session 2: Clinical and Mechanistic Studies 11:05 a.m. - 3:15 p.m.
Chaired by Jedd Wolchok
  11:05 am Charlotte E. Ariyan, Memorial Sloan-Kettering Cancer Center, New York, NY
Enhancing CTLA-4 blockade with local chemotherapy
  11:35 am Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX
From the clinic to the lab: Investigating immune responses to immune checkpoint therapies
  12:05 pm     Lunch
  1:20 pm Roy Herbst, Yale School of Medicine, New Haven, CT
Immune checkpoint therapy for non-small cell lung cancer: Clinical results, biomarker development, and combination therapy
  1:50 pm Neil Segal, Memorial Sloan Kettering Cancer Center, New York, NY
Emerging concepts and therapies: Immunotherapy and GI malignancies
  2:20 pm Harriet Kluger, Yale School of Medicine, New Haven, CT
Immunotherapy in melanoma
   2:50 pm      Refreshment Break
  Session 3: Highlights from the Abstracts 3:15 p.m. - 4:55 p.m.
  3:15 pm Andrea Schietinger, University of Washington, Seattle, WA
Initial tumor-antigen encounters in pre-/early malignant lesions lead to CD8 T cell dysfunction
  3:35 pm
 Matthew M. Gubin, Washington University School of Medicine, St. Louis, MO
Checkpoint blockade cancer immunotherapy targets tumor-specific mutant antigens
  3:55 pm
 Kristen E. Pauken, University of Pennsylvania, Philadelphia, PA
Impact of PD-1 blockade on sustainability of exhausted CD8+ T cell responses
  4:15 pm  ZeNan L. Chang, University of California, Los Angeles, Los Angeles, CA
Chimeric antigen receptor-expressing T cells retain effector function despite Tim-3 and PD-1 upregulation and gain proliferative advantage from CAR-specific cell sorting
  4:35 pm
 Roberta Zappasodi, Memorial Sloan Kettering Cancer Center, New York, NY
Antitumor efficacy of GITR ligation is mediated by Treg inhibition in a pro-inflammatory tumor microenvironment
  5:00 p.m.  Poster Session
 
  Tuesday, October 7, 2014
           
  7:00 am
 Registration and Continental Breakfast
  Session 4: Emerging Therapies
            
  8:00 am Charles Drake, Johns Hopkins University School of Medicine, Baltimore, MD
Combining vaccination with radiation therapy for CNS melanoma: Preclinical studies
  8:30 am Tibor Keler, Celldex Therapeutics, Inc., Hampton, NJ
Development of an anti-CD27 agonist antibody for immunotherapy of cancer
  9:00 am Gregory Beatty, University of Pennsylvania School of Medicine, Philadelphia, PA
Using synthetic biology to restore T cell immunosurveillance in pancreas carcinoma
  9:30 am Holbrook Kohrt, Stanford University School of Medicine, Stanford, CA
Combination immunotherapy to enhance antibody dependent cell mediated cytotoxicity
  10:00 am      Refreshment Break
  10:30 am Hiroyoshi Nishikawa, Osaka University, Osaka, Japan
Regulatory T cells in anti-tumor immunity: Can they be controlled?
  11:00 am David Munn, Georgia Regents University, Augusta, GA 
IDO, Tregs and immune checkpoint pathways
  11:30 am Li Wang, Medical College of Wisconsin, Milwaukee, WI
Harnessing the immune-regulatory role of VISTA for cancer immunotherapy
   12:00 pm    Lunch
  Session 4: Emerging Therapies (cont'd)
           
  1:00 pm Michael Caligiuri, The Ohio State University, Columbus, OH
Human NK cells: Moving into the mainstream of immunotherapy
  1:30 pm F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA
Combination modalities with checkpoint blockade
  2:00 pm David Schaer, Memorial Sloan Kettering Cancer Center; Current address: Eli Lilly and Company, New York, NY
Activating the accelerator and blocking the brake for tumor immunity
  2:30 pm Dmitriy Zamarin, Memorial Sloan-Kettering Cancer Center, New York, NY
Potentiation of immune checkpoint blockade with oncolytic viruses
  3:00 pm      Refreshment Break
  3:30 pm Martin Oft, ARMO Biosciences, Palo Alto, CA
Cancer immunity induced by IL-10
  4:00 pm John Stagg, Institut du cancer de Montréal and University of Montreal, Quebec, Canada
Targeting the adenosine pathway in cancer
  4:30 pm Hassane Zarour, University of Pittsburgh, Pittsburgh, PA
Targeting multiple inhibitory receptors to reverse melanoma-induced T cell dysfunction
 
  Wednesday, October 8, 2014
   8:00 am      Registration and Continental Breakfast
  Session 5: Therapeutics 8:00 a.m. - 11:00 a.m.
           
  9:00 am Irving L. Weissman, Stanford University School of Medicine, Stanford, CA
Normal and neoplastic stem cells
  9:30 am Margaret Shipp, Dana-Farber Cancer Institute, Boston, MA
Genetic basis of immune evasion in lymphoid malignancies
  10:00 am Alexander Lesokhin, Memorial Sloan-Kettering Cancer Center, New York, NY
Myeloid derived suppressor cells as a potential biomarker for cancer immunotherapy
  10:30 am
Dmitry Gabrilovich, The Wistar Institute, Philadelphia, PA
Regulation of myeloid-derived suppressor cells in cancer
 
11:00 am
    

James Allison, The University of Texas MD Anderson Cancer Center, Houston, TX
Closing comments
Select registration type:
Educational Institution/Nonprofit
Full Meeting  (details)
Registration includes admission to all lectures for days selected; you must be registered for Day 2 to attend the Poster Session. Continental breakfast is included daily. Buffet lunch will be provided on days 1 and 2.
Add to calendarMonday, October 06, 2014 - Wednesday, October 08, 2014
  • $695.00 (Standard)
  • $625.00 (Early)
  • $770.00 (Late)

Day 1  (details)
Registration includes admission to all lectures for days selected; you must be registered for Day 2 to attend the Poster Session. Continental breakfast is included daily. Buffet lunch will be provided on days 1 and 2.
Add to calendarMonday, October 06, 2014
  • $350.00 (Standard)
  • $315.00 (Early)
  • $400.00 (Late)

Day 2  (details)
Registration includes admission to all lectures for days selected; you must be registered for Day 2 to attend the Poster Session. Continental breakfast is included daily. Buffet lunch will be provided on days 1 and 2.
Add to calendarTuesday, October 07, 2014
  • $350.00 (Standard)
  • $315.00 (Early)
  • $400.00 (Late)

Day 3  (details)
Registration includes admission to all lectures for days selected; you must be registered for Day 2 to attend the Poster Session. Continental breakfast is included daily. Buffet lunch will be provided on days 1 and 2.
Add to calendarWednesday, October 08, 2014
  • $280.00 (Standard)
  • $245.00 (Early)
  • $330.00 (Late)

 

Contact Information

  • Cancer Research Institute
    (212) 688-7515

© 2020
Quick, easy and affordable online event registration and event management software for all event sizes.